Register for our free email digests:
BOC Group PLC
Latest From Astellas Institute for Regenerative Medicine
Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.
Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.
Chugai is taking concrete steps into the burgeoning regenerative medicine sector in Japan through a new clinical and commercial alliance with a domestic venture for a therapy for knee cartilage disorders.
Mylan adds more than 900 over-the-counter and generic products to its portfolio with the $9.9bn acquisition of Meda. Astellas finalizes the pursuit of Ocata which it began last November.
- Medical Devices
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- BOC Group PLC
- Senior Management
Patrick Rich, Chmn. & CEO
Ian Clubb, Fin. Dir.
- Contact Info
BOC Group PLC
Phone: (44) 27677222
Windlesham, GU2 6HJ
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.